Cellbox Solutions Raises €3.5 Million for Warm-Chain Technology
Cellbox Solutions, a Cologne-based company specializing in portable CO2 incubators, has successfully raised €3.5 million in a Series A funding round. This financing aims to support the global expansion of its innovative warm-chain logistics technology, which facilitates the transport of living cells under controlled physiological conditions. The round was led by the digital business angel network Companisto, with NRW.BANK also participating as an investor.
Company Overview
Cellbox Solutions, founded by Prof Adlkofer, provides technology that enables the safe transport of living cells by maintaining CO2 and temperature-controlled environments. This is crucial for the biotech and research industries where the integrity of live cell samples must be preserved during transport. The company's portable incubators can maintain stable conditions for up to 48 hours, making them a valuable asset for applications such as cell and gene therapies and in vitro fertilization.
Strategic Use of Funds
The newly acquired capital is set to enhance the company's international production and sales activities. Cellbox Solutions plans to leverage this funding to unlock additional applications for its technology across clinical and research environments. The company also aims to establish its warm-chain logistics as a global standard for living cell shipment.
Leadership and Future Plans
In line with its expansion plans, Cellbox Solutions has appointed Dr. Bernd Muehlenweg as Chief Business Officer and Chief Financial Officer. With over 20 years of experience in the life sciences industry, Dr. Muehlenweg brings valuable expertise to the company. He previously held the position of Senior Vice President and Global Head of Business Development for cell therapy at Evotec.
Industry Impact
More than 300 Cellbox devices are currently in use worldwide, serving pharmaceutical companies, biotechnology firms, research institutions, and universities. The technology is certified and compliant with International Air Transport Association regulations, ensuring that it meets the rigorous standards required for air transport.
With this funding round, Cellbox Solutions is poised to further its mission of setting new benchmarks in the transportation of living cells, addressing a critical bottleneck in the life sciences industry. As CEO Prof Adlkofer noted, "By enabling safe, controlled, and reproducible transport under physiological conditions, we address a critical bottleneck in the life sciences industry." The Series A round remains open for additional tranches until May 2026, providing further opportunities for investment.